Latest / Morning Medical with Dr. Chow / Can Money Buy Happiness, AI in Healthcare, and Allergy Medication Risks

Transcript

Can Money Buy Happiness, AI in Healthcare, and Allergy Medication Risks · Morning Medical with Dr. Chow

• 0:00
  Good morning, everyone.
• 0:01
  Welcome to another episode of "Morning Medical with Dr.
• 0:04
  Chow." I'm your host, Dr.
• 0:06
  Chi-Ming Chow.
• 0:07
  As always, I'm here to bring you the latest in medical and health news from around the globe,
• 0:13
  using insights from the cutting edge of artificial intelligence technology.
• 0:17
  Today, we're diving into a fascinating topic that touches on a question as old as time
• 0:22
  itself: Can money really buy happiness?
• 0:26
  According to a recent article in the Harvard Gazette, maybe not.
• 0:30
  But what it can facilitate might surprise you.
• 0:36
  The Harvard Study of Adult Development, directed by Professor Robert Waldinger at
• 0:42
  Harvard Medical School, has been exploring this very question for nearly 87 years.
• 0:48
  It's one of the world's longest-running scientific studies on human health and
• 0:53
  happiness.
• 0:54
  The study started back in 1938 with 724 participants and has now expanded to include
• 1:01
  over 2,500 people, including the wives and descendants of the original participants.
• 1:09
  This extensive research offers a unique glimpse into the factors that contribute to long-term
• 1:13
  health and happiness.
• 1:16
  The key takeaway from this study is that strong relationships are vital.
• 1:21
  As Professor Waldinger famously stated in a TED Talk that has been viewed nearly 50 million
• 1:26
  times, "Good relationships keep us happier and healthier." It's not about wealth, fame, or
• 1:33
  working harder and harder.
• 1:35
  Instead, the study highlights that being more socially connected to family, friends, and
• 1:41
  community leads to greater happiness, better physical health, and a longer life compared to
• 1:46
  those who are less connected.
• 1:49
  The Harvard Study's data spans decades and includes medical records, brain scans,
• 1:54
  in-person interviews, and questionnaires.
• 1:57
  This treasure trove of information is not just useful for Waldinger's team but has also been a
• 2:03
  valuable resource for collaborations with other researchers globally.
• 2:07
  For instance, one collaborative project is examining the effects of lead exposure in
• 2:12
  childhood on long-term physical and mental health.
• 2:15
  This includes potential impacts on juvenile delinquency, educational attainment, and even
• 2:21
  the development of dementia later in life.
• 2:25
  Despite the invaluable insights gained from such longitudinal studies, they face
• 2:29
  significant challenges, particularly in terms of funding.
• 2:33
  The Harvard Study has been primarily supported by grants from the National Institutes of
• 2:37
  Health, and more recently, the National Institute on Aging.
• 2:42
  However, recent funding cuts have raised concerns about the sustainability of long-term
• 2:48
  research projects.
• 2:50
  Professor Waldinger emphasizes that government funding is crucial to support these big
• 2:55
  projects that private foundations are often reluctant to fund over extended periods.
• 3:02
  Beyond the immediate findings, studies like these play a critical role in training the next
• 3:07
  generation of scientists.
• 3:08
  Many young researchers have been trained through the Harvard Study, gaining expertise in
• 3:13
  specialized statistical techniques necessary for longitudinal research.
• 3:17
  There is a growing concern that funding disruptions may deter young scientists from
• 3:22
  pursuing research careers, potentially impacting the country's position as a global
• 3:26
  leader in scientific innovation.
• 3:29
  Professor Waldinger passionately argues that the importance of continuing such research
• 3:35
  extends beyond academia.
• 3:38
  The discoveries made through these studies have fueled economic innovation over the decades.
• 3:44
  If funding cuts persist, not only could scientific progress be stifled, but economic
• 3:49
  advancements might also be jeopardized.
• 3:52
  It's a stark reminder that investing in knowledge and science is as crucial for our
• 3:58
  economic future as it is for our understanding of human health and happiness.
• 4:04
  In a significant policy shift, the United States government has announced that annual
• 4:09
  COVID-19 vaccinations will now be limited primarily to at-risk groups and older
• 4:15
  individuals.
• 4:17
  This change marks a departure from the previous approach that recommended yearly COVID shots
• 4:22
  for the broader population, much like the annual influenza vaccine.
• 4:27
  According to officials from the Food and Drug Administration, the new guidelines will focus
• 4:32
  on making vaccines available to adults aged 65 and over, as well as children and younger
• 4:37
  adults who have at least one health condition that puts them at higher risk.
• 4:43
  This streamlined approach aims to prioritize those who are most vulnerable to severe illness
• 4:47
  from COVID-19.
• 4:49
  However, the decision raises questions about access for individuals who may still wish to
• 4:55
  receive a COVID-19 vaccine but do not fall into these specified groups.
• 5:01
  Dr.
• 5:02
  Paul Offit, a vaccine expert at the Children's Hospital of Philadelphia, expressed concerns
• 5:08
  about how this will affect vaccine availability and insurability, especially for those who do
• 5:14
  not clearly meet the high-risk criteria but still want the protection.
• 5:19
  The framework for this policy was published in the New England Journal of Medicine and is the
• 5:24
  result of ongoing scrutiny of COVID vaccine usage in the United States.
• 5:30
  The move has been led by Health Secretary Robert F.
• 5:33
  Kennedy, who has been critical of the previous "one-size-fits-all" approach to COVID
• 5:38
  vaccinations.
• 5:40
  Officials argue that the United States has been more aggressive than European countries in its
• 5:44
  COVID booster recommendations, particularly for young, healthy adults and children.
• 5:50
  This new policy intends to address these concerns by ensuring that those who are most
• 5:54
  likely to benefit from the vaccine receive it.
• 5:58
  Nevertheless, the Centers for Disease Control and Prevention's advisory panel is set to
• 6:03
  debate the broader implications of this policy next month.
• 6:06
  There are still questions about the overall benefits of annual COVID vaccinations for the
• 6:11
  general population, especially as the virus continues to evolve.
• 6:15
  As we navigate these changes, it's crucial to consider the balance between protecting public
• 6:21
  health and ensuring that vaccines remain accessible to those who need them most.
• 6:27
  This policy shift is a reminder of the ongoing challenges in managing a global pandemic and
• 6:33
  the need for adaptive strategies that reflect the current landscape of the virus.
• 6:40
  In recent news, the Food and Drug Administration has issued a safety alert
• 6:43
  concerning two popular allergy medications: cetirizine, commonly known as Zyrtec, and
• 6:49
  levocetirizine, known as Xyzal.
• 6:52
  These antihistamines are widely used to treat symptoms of allergies such as sneezing, runny
• 6:57
  nose, and itching.
• 6:59
  However, the alert warns about a rare but troubling side effect that some individuals
• 7:04
  experience after discontinuing long-term use of these drugs.
• 7:10
  The Food and Drug Administration reports that some people develop severe itching, also known
• 7:15
  as pruritus, after they stop taking cetirizine or levocetirizine.
• 7:20
  This reaction typically occurs within a few days of discontinuation.
• 7:24
  The prescribing information for these oral allergy medications, available both as
• 7:29
  prescription and over-the-counter forms, will now include warnings about this
• 7:33
  post-discontinuation risk.
• 7:36
  According to the Food and Drug Administration's safety communication, restarting the medication
• 7:41
  resolved the itching for most individuals.
• 7:44
  Additionally, some patients found relief by gradually tapering off the drug after
• 7:49
  restarting it.
• 7:51
  A review of reports to the Food and Drug Administration's Adverse Event Report System
• 7:55
  database revealed that while these cases are rare, they can sometimes be serious and require
• 8:01
  medical intervention.
• 8:03
  Between April 2017 and July 2023, there were 209 reported cases globally of pruritus
• 8:10
  occurring after stopping cetirizine, levocetirizine, or both.
• 8:14
  Notably, 86% of these cases involved cetirizine, and a significant majority, 94%,
• 8:19
  were reported in the United States.
• 8:22
  Interestingly, some users experienced severe itching even after less than one month of using
• 8:27
  the drugs, although most cases involved individuals who used the medication for more
• 8:31
  than three months, with a median duration of 33 months.
• 8:35
  The onset of itching typically happened within two days of stopping the medication, with the
• 8:41
  range being one to five days.
• 8:44
  The post-discontinuation pruritus was often widespread, affecting multiple areas of the
• 8:51
  body, and significantly impacting quality of life.
• 8:55
  Serious outcomes were also documented, including disability in 48 cases,
• 9:01
  hospitalization in three, and even thoughts of suicide or self-harm in two individuals.
• 9:07
  The Food and Drug Administration's alert emphasizes that healthcare providers should
• 9:12
  discuss the risks of pruritus when recommending or prescribing cetirizine or levocetirizine,
• 9:18
  especially if long-term use is anticipated.
• 9:21
  In 90% of the cases, restarting the medication resolved the pruritus, and among those who
• 9:26
  attempted to taper off after restarting, 38% saw their symptoms resolve.
• 9:32
  While the underlying mechanism for this reaction remains unknown, the Food and Drug
• 9:37
  Administration's evaluation supports a causal relationship between stopping cetirizine or
• 9:44
  levocetirizine and the onset of pruritus.
• 9:49
  Beyond prolonged usage, no additional risk factors have been identified.
• 9:54
  These antihistamines are approved for treating seasonal allergic rhinitis in individuals aged
• 10:00
  two years and older, and for perennial allergic rhinitis and chronic idiopathic urticaria in
• 10:07
  those six months and older.
• 10:10
  Cetirizine has been available over the counter since 2007, and levocetirizine since 2017.
• 10:17
  In 2022 alone, more than 60 million packages of these over-the-counter drugs were sold at
• 10:23
  retail outlets across the United States.
• 10:26
  It's important for both patients and healthcare providers to be aware of these potential risks,
• 10:32
  especially given the widespread use of these medications.
• 10:37
  In today's rapidly evolving world of healthcare, artificial intelligence is often
• 10:42
  heralded as a game-changer.
• 10:44
  But with all its potential, there are cautionary tales to heed.
• 10:49
  Dr.
• 10:50
  Justin Norden, a Stanford professor and CEO of Qualified Health, offers some critical advice
• 10:56
  on deploying artificial intelligence in healthcare settings.
• 11:01
  Dr.
• 11:02
  Norden highlights that while there's tremendous excitement about artificial intelligence in
• 11:06
  healthcare, the real challenge lies in understanding what artificial intelligence can
• 11:11
  actually deliver.
• 11:12
  He emphasizes that healthcare providers should focus on identifying return on investment,
• 11:18
  safety issues, risk, governance, and long-term value when considering artificial intelligence
• 11:24
  systems and tools.
• 11:26
  Despite the buzz around artificial intelligence, Dr.
• 11:29
  Norden points out that even the most widely adopted use cases, like ambient documentation,
• 11:34
  have not consistently delivered financial returns.
• 11:37
  Instead, the true value of artificial intelligence today is found in healthcare
• 11:42
  operations.
• 11:43
  Artificial intelligence can unlock insights from unstructured data, aiding in tasks like
• 11:48
  quality reporting and improving revenue cycle workflows.
• 11:53
  These operational improvements may seem small, but they collectively have a significant
• 11:57
  impact.
• 11:59
  Dr.
• 12:00
  Norden also warns that many healthcare professionals are already using artificial
• 12:05
  intelligence tools unofficially, which poses a risk.
• 12:08
  He stresses the need for healthcare organizations to bring artificial intelligence
• 12:13
  "above the table," making it secure and compliant with the Health Insurance Portability
• 12:17
  and Accountability Act.
• 12:19
  This approach ensures that artificial intelligence becomes a part of system-wide
• 12:24
  progress rather than operating in the shadows.
• 12:28
  Another area of caution is the use of public-facing artificial intelligence chat
• 12:33
  tools.
• 12:33
  While they can be impressive, these systems are vulnerable to exploitation and could lead to
• 12:38
  data leaks or harmful patient interactions.
• 12:41
  Dr.
• 12:42
  Norden advises that the safer path forward involves internal deployment of artificial
• 12:47
  intelligence in secure environments, with human oversight to ensure safe and effective use.
• 12:53
  Dr.
• 12:54
  Norden also underscores the importance of managing risk, governance, and long-term value
• 12:59
  without succumbing to the hype.
• 13:01
  Many health systems are cautious, opting for pilots and side projects without a clear path
• 13:07
  forward.
• 13:08
  He advocates for clear leadership and direction on which tools to use and how to measure
• 13:12
  success, emphasizing the need for scalable, secure, and valuable internal tools.
• 13:19
  The journey with artificial intelligence in healthcare is not just about technology but
• 13:23
  also about empowering people.
• 13:25
  Dr.
• 13:27
  Norden notes that many staff members are already using artificial intelligence tools in
• 13:32
  their personal lives, and organizations should harness this interest by providing secure and
• 13:37
  effective tools for professional use.
• 13:41
  Education and ongoing training are essential to guide safe, responsible, and effective use of
• 13:47
  artificial intelligence.
• 13:50
  As we conclude today's episode, it's clear that while artificial intelligence holds great
• 13:54
  promise for transforming healthcare, it requires careful implementation and oversight.
• 14:00
  The future of artificial intelligence in healthcare is not just about technological
• 14:05
  advancement but about integrating it wisely into the fabric of healthcare operations and
• 14:10
  patient care.
• 14:12
  Thank you for tuning in to "Morning Medical with Dr.
• 14:15
  Chow." Stay informed, stay healthy, and we'll see you next time.